维普中文期刊产品整合服务
15篇 您的检索式:作者名="Verrou E"
    题名 作者 年代 出处 被引量
1Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-center experience in 303 patients显示文摘Zervas K Verrou E Teleioudis Z 2006Br J Haematol2006,134,6:1
2Longi- tudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw 显示文摘Vahtsevanos K Kyrgidis A Verrou E 2009J Clin Oncol2009,27,32:1
3Response of primary plasma cell leukemia to the com- bination of bortezomib and dexamethasone:do specific cytogenetic and immunophenotypic characteristics in- fluence treatment outcome显示文摘KATODRITOU E VERROU E GASTARI V 2008? Leuk Res2008,32,:1
4Erythropoiesis?stimulating agents are associated with reduced survival in patients with multiple myeloma 显示文摘Katodritou E Verrou E Hadjiaggelidou C 2008Am J Hematol2008,83,9:1
5incidence risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single - centre experience in 303 patients 显示文摘Zervas K Verrou E Teleioudis Z 2006Br J Haematol2006,134,6:1
6Incidence,risk faetors and management of osteonecrcsis of the jaw in patients with multiple myeloma:a single-centre experience in 303 patients显示文摘Zervas K Verrou E Teleioudis Z 0,,06:1
7Extramedullary (EMP) relapse in unusual locations in multiple myeloma: Is there an association with precedent thalidomide administration and a correlation of special biological features with treatment and outcome? 显示文摘KATODRITOU E GASTARI V VERROU E 2009Leuk Res2009,33,8:1
8Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone:do specific cytogenetic and immunophenotypic characteristics influence treatment outcome显示文摘Katodritou E Verrou E GastariV 0,,07:1
9Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone:do specific cytogenetic and immunophenotypic characteristics influence treatment outcome? 显示文摘Katodritou E Verrou E Gastari V 2008Leuk Res2008,32,7:1
10Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone:do specific cytogenetic and immunophenotypic characteristics influence treatment outcome显示文摘Katodritou E Verrou E Gastari V 0,,07:1
11Response of primary plasma cell leukemia to the combi- nation of bortezomib and dexamethasone : do specific cy- togenetic and immunophenotypie eharaeteristics influ- ence treatment outcome? 显示文摘KATODRITOU E VERROU E GASTARI V 2008Leuk Res2008,32,7:1
12Extramedullary (EMD)relapse in unusual locations in multiple myeloma: Is there anassociation with precedent thalidomide administration and acorrelation of special biological features with treatment andoutcome显示文摘Katodritou E Gastari V Verrou E 2009Leuk Res2009,33,8:1
13Incidence,risk factors and management of osteonecrosis of the jaw in patients with multiple mydoma:a single-centre experience in 303 patients显示文摘Zervas K Verrou E Teleioudis Z 2006Br J Haematol2006,134,6:1
14Incidence,risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma:a single-centre experience in 303 patients显示文摘ZERVAS K VERROU E TELEIOUDIS Z 2006Br JHaematol2006,134,:1
15Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw 显示文摘Vahtsevanos K Kyrgidis A Verrou E 2009J Clin Oncol2009,27,321:1
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费